Search Results

To join our waitlist please fill out this form - https://forms.gle/xPZjX56LkEvhGv6b6 We'll let you course is to give the registrant a good overall understanding of the unique science of pharmacology and how Sessions will include a 1-hour live lecture plus 30 minutes of Q&A. Every participant will also get the chance to have a 1:1 meeting with Dr.

this mini video course, I want to walk you through our new website and show you what the ecosystem has

Main objectives: - Learning how to perform advanced GPCR pharmacology data analysis in support of drug The increased understanding will also be helpful for the participants in their training and education Sessions will include a one-hour live lecture plus one hour of Q&A and discussion. Every participant will also have a 1:1 meeting with Dr. Hoare during or after the four weeks, scheduled according to the professor's availability.

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM

August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology We recently reported the initial characterization of a NanoBRET-based conformational histamine H3 receptor In the current study, we have further characterized this H3R biosensor on intact cells by monitoring In addition, we have validated the H3R biosensor in membrane preparations and found that observed potency Hence, the H3R conformational biosensor in membranes might be a ready-to-use, high-throughput alternative

Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs. Listen where you get your podcasts https://www.ecosystem.drgpcr.com/dr-gpcr-podcast #gpcr #drgpcr #podcast

Here we used a dataset of mutations found in patient samples derived from the Genomic Data Commons and compared it to the natural human variance as exemplified by data from the 1000 genomes project. We subsequently created a ranking of high scoring GPCRs, using a multi-objective approach (Pareto Front Authors Bongers B J , Gorostiola González M , Wang X , van Vlijmen HWT , Jespers W , Gutiérrez-de-Terán H , Ye K , IJzerman AP , Heitman LH , van Westen GJP.

Timo De Groof About Dr. Timo De Groof Dr. Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry In the near future, Timo hopes to combine his previous GPCR experience with his current focus to set Timo De Groof on the web LinkedIn Researchgate Twitter Medical Imaging Group Google Scholar Dr.

Following his Ph.D. in Neurological Sciences at the same university in 1985, he completed a post-doctoral Council of Canada at the Faculty of Medicine of the Université de Montréal. Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. His work received more than 30,000 citations yielding an h-index of 95. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.